MUMBAI, India, Oct. 18, 2023 /PRNewswire/ -- The Pharma Solutions (PPS) business of Piramal Pharma Limited, a leading contract development and manufacturing organization (CDMO), today formally announced the launch of a world-class high throughput that augments existing in vitro biology capabilities at its drug discovery services site in Ahmedabad, India. This new expansion significantly adds primary and secondary screening capabilities for compounds prepared at the Ahmedabad site.
With this expansion, Piramal Pharma Solutions is uniquely positioned to provide clients with an integrated set of discovery capabilities and leverage a broad range of in vitro screening technology tools to support its broad portfolio of research services. The goal is to generate data that provides a superior data package for clients and enhance the company's value as an outsourcing partner. The benefits of this new investment will be seen in an improved experience for customers of PPS discovery services. Integrating chemistry and biology services under one roof promises to add high efficiency to the discovery process. To enable this expansion, PPS is committed to recruiting experienced staff with a demonstrated track record in biology services, complementing existing technical and operational expertise.
Peter DeYoung, CEO of Piramal Pharma Solutions, explained: "Through these enhanced in vitro biology services, our drug discovery team will be able to provide customers with information that allows them to make decisions sooner and will be an even more effective partner in the drug discovery process.
The new high-throughput screening format allows PPS to screen and screen large collections using various assay platform technologies including, but not limited to, TR-FRET (Time Resolved Fluorescence Resonance Energy Transfer)/HTRF (Homogeneous Fluorescence time resolved), Fluorescence Polarization (FP), absorbance, Luminescence/Electrochemiluminescence (ECL), AlphaScreen, LanthaScreen, flow cytometry and high content imaging. These platforms will be applicable to a variety of targets including, but not limited to, G protein-coupled receptors (GPCRs) and kinases.
About Piramal Pharma Solutions
Piramal Pharma Solutions (PPS) is a contract development and manufacturing organization (CDMO) that offers end-to-end development and manufacturing solutions across the entire life cycle of medicines. We serve our customers through an integrated global network of facilities in North America, Europe and Asia. This allows us to offer a wide range of services including drug discovery solutions, pharmaceutical and process development services, clinical trial supplies, commercial supply of APIs and finished dosage forms. We also offer specialized services, such as the development and manufacturing of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent oral solid drug products. PPS also offers development and manufacturing services for biologics, including vaccines and gene therapies, made possible through Piramal Pharma Limited's sister company, Yapan Bio Private Limited.
For more information, visit: www.piramalpharmasolutions.com | LinkedIn| Facebook | Twitter
About Piramal Pharma Limited
Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract manufacturing and development organization; Piramal Critical Care (PCC), a complex hospital generics company; and the India Consumer Healthcare business, which sells over-the-counter products. Additionally, one of PPL's associate companies, Allergan India Private Limited, is a joint venture with AbbVie Inc. and has emerged as one of the market leaders in the area of ophthalmic therapy. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.
For more information, visit: www.piramal.com/pharma | LinkedIn | Facebook | Twitter
Photo - https://mma.prnewswire.com/media/2249854...Photo - https://mma.prnewswire.com/media/2249857...Photo - https://mma.prnewswire.com/media/ 2249859...Photo - https://mma.prnewswire.com/media/2249861...Photo - https://mma.prnewswire.com/media/2249856...Logo - https://mma.prnewswire. com/media/1726186...
View original content: https://www.prnewswire.com/es/comunicados-de-prensa/piramal-pharma-solutions-lanza-capacidades-de-biologia-in-vitro-en-el-sitio-de-ahmedabad-discovery-services-301960517.html
